The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Open accessAbstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [20]
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [21]
In the citing paper
“Nevertheless, measurement and treatment of blood lipids, blood pressure, and glucose levels have became the major emphases for cardiovascular risk reduction.”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,060
Reddy, V. S., Bui, Q. T., Jacobs, J. R., Begelman, S. M., Miller, D. P., & French, W. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.12.006 · Cited by 134
Carroll, J., Seeman, T. E., Olmstead, R. E., Melendez, G., Sadakane, R., Bootzin, R. R., Nicassio, P. M., & Irwin, M. R. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.02.010 · Cited by 140
Agnelli, G., Cimminiello, C., Meneghetti, G., & Urbinati, S. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02225.x · Cited by 139
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Kasichayanula, S., Grover, A., Emery, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Gibbs, J. P. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0620-7 · Cited by 135
Taylor, A. J., Bindeman, J., Feuerstein, I. M., Le, T. P., Bauer, K., Byrd, C., Wu, H., & O’Malley, P. G. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.069 · Cited by 135
Digital Mammography and Screening for Coronary Artery Disease
Margolies, L. R., Salvatore, M. M., Hecht, H. S., Kotkin, S., Yip, R., Baber, U., Bishay, V. L., Narula, J., Yankelevitz, D. F., & Henschke, C. I. (2016) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2015.10.022 · Cited by 135
Risk of Myocardial Infarction or Vascular Death After First Ischemic Stroke
Dhamoon, M. S., Tai, W., Boden-Albala, B. M., Rundek, T., Paik, M. C., Sacco, R. L., & Elkind, M. S. V. (2007) · Stroke · doi:10.1161/strokeaha.106.480988 · Cited by 135
Nicotinic acid: an old drug with a promising future
Bodor, E. T., & Offermanns, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707528 · Cited by 136
Bellary, S., O'Hare, J., Raymond, N., Gumber, A., Mughal, S., Szczepura, A., Kumar, S., & Barnett, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60764-3 · Cited by 135
Determinants of magnetic resonance imaging detected carotid plaque components: the Rotterdam Study
van den Bouwhuijsen, Q. J. A., Vernooij, M. W., Albert Hofman, D., Krestin, G. P., van der Lugt, A., & Witteman, J. C. M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr227 · Cited by 134
Græbe, M., Pedersen, S., Borgwardt, L., Højgaard, L., Sillesen, H. H., & Kjær, A. (2008) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2008.11.018 · Cited by 134
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade
Fleischmann, K. E., Beckman, J. A., Buller, C. E. H., Calkins, H. G., Fleisher, L. A., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., Robb, J. F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.004 · Cited by 135
National lipid association annual summary of clinical lipidology 2016
Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128
Druss, B. G., von Esenwein, S. A., Glick, G. E., Deubler, E. L., Lally, C. A., Ward, M. C., & Rask, K. J. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050507 · Cited by 140
Guevara-Cruz, M., Tovar, A. R., Aguilar-Salinas, C. A., Medina-Vera, I., Gil-Zenteno, L., Hernández-Viveros, I., López-Romero, P., Ordaz-Nava, G., Canizales-Quinteros, S., Guillen Pineda, L. E., et al. (2012) · The Journal of Nutrition · doi:10.3945/jn.111.147447 · Cited by 132
Hyre, A. D., Muntner, P., Menke, A., Raggi, P., & He, J. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.01.032 · Cited by 132
Pletcher, M. J., Bibbins-Domingo, K., Liu, K., Sidney, S., Lin, F., Vittinghoff, E., & Hulley, S. B. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00004 · Cited by 129
Madhwal, S., Atreja, A., Albeldawdi, M., López, R., Post, A. B., & Costa, M. (2012) · Liver Transplantation · doi:10.1002/lt.23508 · Cited by 131
Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease
Hayward, R. A., Krumholz, H. M., Zulman, D. M., Timbie, J. W., & Vijan, S. S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00004 · Cited by 130
Egan, C. G., Lavery, R., Caporali, F., Fondelli, C., Pasini, F. L., Dotta, F., & Sorrentino, V. (2008) · Diabetologia · doi:10.1007/s00125-008-0939-6 · Cited by 130
Simpson, R. J., & Mendys, P. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.026 · Cited by 131
Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting
Cziraky, M. J., Watson, K. E., & Talbert, R. L. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s8-a.1 · Cited by 134
Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130
Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation · doi:10.1161/circulationaha.116.024604 · Cited by 127
Kimball, A. B., Szapary, P. O., Mrowietz, U., Reich, K., Langley, R. G. B., You, Y., Hsu, M.-C., Yeilding, N. M., Rader, D. J., & Mehta, N. N. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.06.035 · Cited by 134
Statins, Risk of Diabetes, and Implications on Outcomes in the General Population
Wang, K.-L., Liu, C., Chao, T., Huang, C.-M., Wu, C., Chen, S., Chen, T., Lin, S., & Chiang, C. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.05.019 · Cited by 132
Gibson, C. M., Pride, Y. B., Hochberg, C. P., Sloan, S., Sabatine, M. S., & Cannon, C. P. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.010 · Cited by 132
Diagnosis and management of the metabolic syndrome in obesity
Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00221.x · Cited by 131
Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba
Hall, K., Murrell, J., Ogunniyi, A., Deeg, M., Baiyewu, O., Gao, S., Gureje, O., Dickens, J., Evans, R., Smith-Gamble, V., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194507.39504.17 · Cited by 128
Orasanu, G., Ziouzenkova, O., Devchand, P. R., Nehra, V., Hamdy, O., Horton, E. S., & Plutzky, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.055 · Cited by 131
Backes, J. M., Venero, C. V., Gibson, C., Ruisinger, J. F., Howard, P. A., Thompson, P. D., & Moriarty, P. M. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k604 · Cited by 127
Cardiometabolic effects of psychotropic medications
Abosi, O. J., Lopes, S., Schmitz, S. L., & Fiedorowicz, J. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0065 · Cited by 135
Prevalence and control of dyslipidemia among persons with diabetes in the United States
Jacobs, M. J., Kleisli, T., Pio, J. R., Malik, S., L'Italien, G. J., Chen, R. S., & Wong, N. D. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.032 · Cited by 126
Saddichha, S., Manjunatha, N., Ameen, S., & Akhtar, S. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.004 · Cited by 130
Roth, E. M., Moriarty, P. M., Bergeron, J., Langslet, G., Manvelian, G. Z., Zhao, J. M., Baccara‐Dinet, M. T., & Rader, D. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.043 · Cited by 128
Rosenzweig, J. L., Bakris, G. L., Berglund, L., Hivert, M., Horton, E. S., Kalyani, R. R., Murad, M. H., & Vergès, B. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01338 · Cited by 133
Makover, M. E., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100371 · Cited by 139
Argo, C. K., Loria, P., Caldwell, S. H., & Lonardo, A. (2008) · Hepatology · doi:10.1002/hep.22402 · Cited by 132
deGoma, E. M., Leeper, N. J., & Heidenreich, P. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.086 · Cited by 125
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Carter, J.-P. L., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub3 · Cited by 123
Nash, M. S., Groah, S. L., Gater, D. R., Dyson-Hudson, T. A., Lieberman, J. A., Myers, J., Sabharwal, S., Taylor, A. J., & Consortium for Spinal Cord Medicine (2018) · Topics in Spinal Cord Injury Rehabilitation · doi:10.1310/sci2404-379 · Cited by 126
Choi, I. H., Noh, J. S., Han, J.-S., Kim, H. J., Han, E.-S., & Song, Y. O. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.2563 · Cited by 126
Ridker, P. M., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Khurmi, N. S., Köenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.072 · Cited by 125
Hirsch, A. T., Haskal, Z. J., HERTZER, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.024 · Cited by 129
Self-citationBerryman, C. E., Preston, A. G., Karmally, W., Deckelbaum, R. J., & Kris‐Etherton, P. M. (2011) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00383.x · Cited by 128
Choi, S.-Y., Kim, D., Kim, H. J., Kang, J. H., Chung, S. J., Park, M. J., Kim, Y. S., Kim, C. H., Choi, S. H., Kim, W. K., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.238 · Cited by 126
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
Akdim, F., Tribble, D. L., Flaim, J., Yu, R. Z., Su, J. Q., Geary, R. S., Baker, B. F., Fuhr, R., Wedel, M. K., & Kastelein, J. J. P. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr148 · Cited by 123
Risk factors for statin‐associated rhabdomyolysis
Schech, S. D., Graham, D. J., Staffa, J. A., Andrade, S. E., Grenade, L. L., Burgess, M., Blough, D. K., Stergachis, A. S., Chan, K. A., Platt, R. G., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1287 · Cited by 125
Wong, W. B., Lin, V. W., Boudreau, D. M., & Devine, E. B. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3381 · Cited by 124
Effect of dosing frequency on chronic cardiovascular disease medication adherence
Coleman, C. I., Roberts, M. S., Sobieraj, D. M., Lee, S., Alam, T., & Kaur, R. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.677419 · Cited by 125
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)
Committee for the Korean Guidelines for the Management of Dyslipidemia (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.3.275 · Cited by 123
Insulin resistance – a common link between type 2 diabetes and cardiovascular disease
Lebovitz, H. E. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00521.x · Cited by 125
An assessment by the Statin Diabetes Safety Task Force: 2014 update
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.02.012 · Cited by 119
Self-citationSabeti, S., Schlager, O., Exner, M., Mlekusch, W., Amighi, J., Dick, P., Maurer, G., Huber, K., Koppensteiner, R., Wagner, O. F., et al. (2007) · Stroke · doi:10.1161/strokeaha.107.488387 · Cited by 123
Bardini, G., Rotella, C. M., & Giannini, S. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.82 · Cited by 124
Abdominal Obesity, Body Mass Index, and Hypertension in US Adults: NHANES 2007–2010
Ostchega, Y., Hughes, J. P., Terry, A. L., Fakhouri, T. H. I., & Miller, I. M. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2012.120 · Cited by 123
Chung, C. P., Giles, J. T., Petri, M., Szklo, M., Post, W. S., Blumenthal, R. S., Gelber, A. C., Ouyang, P., Jenny, N. S., & Bathon, J. M. (2012) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2011.07.004 · Cited by 122
Statins for prevention of atrial fibrillation after cardiac surgery: A systematic literature review
Liakopoulos, O. J., Choi, Y., Kuhn, E. W., Wittwer, T., Borys, M., Madershahian, N., Wassmer, G., & Wahlers, T. (2009) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2009.03.054 · Cited by 122
Chapman, M. J., & Sposito, A. C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.004 · Cited by 123
Monitoring Cholesterol Levels: Measurement Error or True Change?
Glasziou, P., Irwig, L., Heritier, S. R., Simes, R. J., Tonkin, A. M., & for the LIPID Study Investigators (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00005 · Cited by 121
Rigo, F., Sicari, R., Gherardi, S., Djordjevic-Dikic, A., Cortigiani, L., & Picano, E. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm527 · Cited by 121
Simvastatin suppresses experimental aortic aneurysm expansion
Kalyanasundaram, A., Elmore, J. R., Manazer, J. R., Golden, A. M., Franklin, D. P., Galt, S. W., Zakhary, E. M., & Carey, D. J. (2006) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.08.007 · Cited by 121
The Relationship between Retinal Microvascular Abnormalities and Coronary Heart Disease: A Review
McClintic, B. R., McClintic, J. I., Bisognano, J. D., & Block, R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.030 · Cited by 123
Goldberg, R. B., Guyton, J. R., Mazzone, T., Weinstock, R. S., Polis, A. B., Edwards, P., Tomassini, J. E., & Tershakovec, A. M. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.12.1579 · Cited by 121
Nissen, S. E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.013 · Cited by 119
Inflammation, Atherosclerosis, and Stroke
Elkind, M. S. V. (2006) · The Neurologist · doi:10.1097/01.nrl.0000215789.70804.b0 · Cited by 120
Álvaro, A., Solà, R., Rosales, R., Ribalta, J., Anguera, A., Masana, L., & Vallvé, J.-C. (2008) · IUBMB Life · doi:10.1002/iub.110 · Cited by 120
Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway
Do, R., Kiss, R., Gaudet, D., & Engert, J. C. (2008) · Clinical Genetics · doi:10.1111/j.1399-0004.2008.01099.x · Cited by 118
Artichoke leaf extract for treating hypercholesterolaemia
Wider, B., Pittler, M. H., Coon, J. T., & Ernst, E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003335.pub3 · Cited by 121
RetractedBenn, M. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.004 · Cited by 119
Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets
DiRienzo, D. B. (2013) · Nutrition Reviews · doi:10.1111/nure.12084 · Cited by 120
The Effects of Barley-Derived Soluble Fiber on Serum Lipids
Talati, R., Baker, W. L., PABILONIA, M. S., White, C. M., & Coleman, C. I. (2009) · The Annals of Family Medicine · doi:10.1370/afm.917 · Cited by 119
Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali, A. C., & BIA, M. J. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05081107 · Cited by 119
Cao, Y., Zou, L., Li, W., Yu, S., Zhao, G., & Hu, Y. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.241 · Cited by 125
Toms, T. E., Panoulas, V. F., John, H., Douglas, K., & Kitas, G. D. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2765 · Cited by 119
Schnipper, J. L., Linder, J. A., Palchuk, M. B., Einbinder, J. S., Li, Q., Postilnik, A., & Middleton, B. (2008) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m2501 · Cited by 121
Garg, A., & Simha, V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0275 · Cited by 89
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel, T. N., Shishehbor, M. H., & Bhatt, D. L. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl445 · Cited by 119
Feig, J. E., Vengrenyuk, Y., Reiser, V., Wu, C., Statnikov, A., Aliferis, C. F., Garabedian, M. J., Fisher, E. A., & Puig, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039790 · Cited by 118
Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia
Fentoğlu, Ö., Köroğlu, B. K., Hiçyılmaz, H., Sert, T., Özdem, M., Sütçü, R., Tamer, M. N., Orhan, H., Ay, Z. Y., Tonguç, M. Ö., et al. (2010) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2010.01644.x · Cited by 119
Robinson, J. G., & Goldberg, A. C. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.451 · Cited by 120
Kadish, A. H., Bello, D. B., Finn, J. P., Bonow, R. O., Schaechter, A., Subacius, H. P., Albert, C. M., Daubert, J. P., Fonseca, C. G., & Goldberger, J. J. (2009) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2009.01503.x · Cited by 118
Chimowitz, M. I., Lynn, M., Turan, T. N., Fiorella, D., Lane, B. F., Janis, S., & Derdeyn, C. P. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.05.001 · Cited by 118
mTOR Inhibitors in Advanced Renal Cell Carcinoma
Voss, M. H., Molina, A. M., & Motzer, R. J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.008 · Cited by 119
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
Sniderman, A. D., Couture, P., & Graaf, J. D. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.50 · Cited by 118
Jones, P. H., Nair, R., & Thakker, K. M. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.001800 · Cited by 119
Dyslipidemia and Diabetic Retinopathy
Chang, Y., & Wu, W. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.121 · Cited by 117
Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action
Nagao, M., Nakajima, H., Toh, R., Hirata, K., & Ishida, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17025 · Cited by 124
National Trends in Statin Use by Coronary Heart Disease Risk Category
Ma, J., Sehgal, N. L., Ayanian, J. Z., & Stafford, R. S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020123 · Cited by 118
Three Reasons to Abandon Low-Density Lipoprotein Targets
Hayward, R. A., & Krumholz, H. M. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.964676 · Cited by 115
Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction
He, F., Lv, P., Zhao, X. Y., Wang, X., Ma, X., Meng, W., Meng, X., & Dong, S. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2089-0 · Cited by 120
Ye, Y., Chen, X. D., Han, J. J., Jiang, W., Natarajan, P., & Zhao, H. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003128 · Cited by 119
Apolipoproteins as markers and managers of coronary risk
Chan, D. C. (2006) · QJM · doi:10.1093/qjmed/hcl027 · Cited by 117
Effect of combining psyllium fiber with simvastatin in lowering cholesterol
Moreyra, A. E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1161 · Cited by 117
Sampson, U. K. A., Linton, M. F., & Fazio, S. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283470359 · Cited by 118
Corriere, T., Marca, S. D., Cataudella, E., Pulvirenti, A., Alaimo, S., Stancanelli, B., & Malatino, L. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.022 · Cited by 116
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance
Grundy, S. M. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80005-0 · Cited by 116
Self-citationSniderman, A. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.12.006 · Cited by 116
Schaefer, E. J., McNamara, J. R., Asztalos, B. F., Tayler, T., Daly, J. A., Gleason, J. L., SEMAN, L. J., Ferrari, A., & Rubenstein, J. J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.01.023 · Cited by 116
Parish, S., Peto, R., Palmer, A. J., Clarke, R. T., Lewington, S., Offer, A. R., Whitlock, G., Clark, S., Youngman, L. D., Sleight, P., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp221 · Cited by 121
Metadata
- Authors
- Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
- Affiliations
- American College of Cardiology (US)
- Venue
- Circulation
- Published
- 2004-07-13
- Volume
- 110
- Issue
- 2
- Pages
- 227-239
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106343349
- Cited by
- 6,902
- References
- 54
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
- FWCI
- 539.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2004-08-10)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Heart Association
- American College of Cardiology Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
- MeSH terms
- Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
